Δημοσιεύσεις

Koutsogianni AD, Barkas F, Tellis C, Tselepis A, Liamis G, Tsimikas S, Liberopoulos E. Effect of lipid-lowering medications on oxidized phospholipids in individuals with elevated lipoprotein(a). Atheroscler Plus 2025;61:58–66.

Ceasovschih A, Balta A, Aldeen ES, Bianconi V, Barkas F, Şener YZ, Jakubová M, Yilmaz MB, Banach M, Șorodoc L, Șorodoc V. Sodium-glucose cotransporter 2 inhibitors and atherosclerosis. Am J Prev Cardiol 2025;23:101061.

Kolios NG, Barkas F, Ntaios G, Milionis H. Strategic lowering of LDL-cholesterol post ischemic stroke: identifying optimal targets, timing, and therapeutic approaches. Thromb Haemost 2025.

Brandts J, Barkas F, De Bacquer D, Jennings C, De Backer GG, Kotseva K, Ryden L, Lip GYH, Erlund I, Ganly S, Vihervaara T, Adamska A, Abreu A, Almahmeed W, Ambari AM, Ge J, Hasan-Ali H, Huo Y, Jankowski P, Jimenez RM, Li Y, Zuhdi ASM, Makubi A, Mbakwem AC, Mbau L, Estrada JLN, Ogah OS, Ogola EN, Quintero-Baiz A, Sani MU, Liprandi MIS, Tan JWC, Triana MAU, Yeo TJ, Wood D, McEvoy JW, Ray KK. International patterns in lipid management and implications for patients with coronary heart disease: results from the INTERASPIRE study. Eur J Prev Cardiol 2025.

Giannakopoulou SP, Barkas F, Chrysohoou C, et al. Comparative analysis of obesity indices in discrimination and reclassification of cardiovascular disease risk: The ATTICA study (2002–2022). Eur J Intern Med 2025;134:96–103.

Elshorbagy A, Vallejo-Vaz AJ, Barkas F, et al. Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry. Eur Heart J 2025;46:1127–1140.

Barkas F, Brandts J, De Bacquer D, et al. Global variation in lipoprotein(a) levels among patients with coronary heart disease: insights from the INTERASPIRE study and implications for emerging Lp(a)-lowering therapies. J Am Coll Cardiol 2025;85:2028–2042.

Stevens CAT, Vallejo-Vaz AJ, Chora JR, et al. Improving the detection of potential cases of familial hypercholesterolemia: could machine learning be part of the solution? J Am Heart Assoc 2024;13:e034434.

Barkas F, Sener YZ, Golforoush PA, et al. Advancements in risk stratification and management strategies in primary cardiovascular prevention. Atherosclerosis 2024;395:117579.

Barkas F, Rizos CV, Liamis G, et al. Obesity and atherosclerotic cardiovascular disease in adults with heterozygous familial hypercholesterolemia: an analysis from HELLAS-FH registry. J Clin Lipidol 2024;18:e394–e402.

Barkas F, Ray K. An update on inclisiran for the treatment of elevated LDL cholesterol. Expert Opin Pharmacother 2024;25:349–358.

Barkas F, Ray KK. The global diagnostic network: what can we learn from half a billion lipid measurements between 2018 and 2020? Eur Heart J 2023;44:2319–2321.

Barkas F, Bathrellou E, Nomikos T, et al. Plant sterols and plant stanols in cholesterol management and cardiovascular prevention. Nutrients 2023;15.

Barkas F, Filippas-Ntekouan S, Kosmidou M, et al. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis. Rheumatology (Oxford) 2021;60:5527–5537.

Barkas F, Nomikos T, Liberopoulos E, Panagiotakos D. Diet and cardiovascular disease risk among individuals with familial hypercholesterolemia: systematic review and meta-analysis. Nutrients 2020;12.

Barkas F, Liamis G, Elisaf M, Anastasiou G, Liberopoulos E. Metabolically healthy obesity and risk of incident type 2 diabetes in 1077 statin-treated individuals: a six-year retrospective study. Eur J Prev Cardiol 2020;27:2341–2344.

Barkas F, Elisaf M, Rizos EC, Liberopoulos E. Bridging the treatment gap in patients at ‘extreme’ cardiovascular risk: evidence from a lipid clinic. Atherosclerosis 2019;281:216–218.

Barkas F, Elisaf M, Milionis H. Protection against stroke with glucagon-like peptide 1 receptor agonists: a systematic review and meta-analysis. Eur J Neurol 2019;26:559–565.

Barkas F, Elisaf M, Liberopoulos E, et al. Atherogenic dyslipidemia increases the risk of incident diabetes in statin-treated patients with impaired fasting glucose or obesity. J Cardiol 2019;74:290–295.

Barkas F, Elisaf M, Kalaitzidis R, Liamis G. Uric acid and incident chronic kidney disease in dyslipidemic individuals. Curr Med Res Opin 2018;34:1193–1199.

Barkas F, Elisaf M, Tsimihodimos V, Milionis H. Dipeptidyl peptidase-4 inhibitors and protection against stroke: a systematic review and meta-analysis. Diabetes Metab 2017;43:1–8.

Barkas F, Elisaf M, Liberopoulos E, et al. Statin therapy with or without ezetimibe and the progression to diabetes. J Clin Lipidol 2016;10:306–313.

Barkas F, Elisaf M, Milionis H. Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: a systematic review and meta-analysis. Atherosclerosis 2015;243:60–64.